PhRMA Funnels Millions to Groups Fighting Drug Pricing Reforms
The pharma lobby gave more than $16 million in 2022 to advocacy groups, many of them ostensibly “grassroots,” that are battling the Medicare drug price negotiations now underway.
The pharma lobby gave more than $16 million in 2022 to advocacy groups, many of them ostensibly “grassroots,” that are battling the Medicare drug price negotiations now underway.
Susie Wiles of Mercury Public Affairs, a senior advisor to Trump's campaign, is lobbying for Swisher as it fights a proposal meant to reduce youth smoking.
The maker of Ozempic and Wegovy has recently hired a dozen new lobbyists to work on the issue of obesity and medication coverage.
The pharmaceutical giant spent big bucks amid key international negotiations last year to protect record earnings.
As a consumer protection subcommittee chairman, Blumenthal has focused on the role pharmaceutical benefit managers play in driving up the cost of drugs.
Lobbying giant PhRMA reported revenues of more than $600 million in 2021, a new record for the group.
Carr squeaked out a re-election win over a Democratic rival who pledged that she would not enforce Georgia's "heartbeat law" abortion ban.
In a letter to Ag Secretary Tom Vilsack, the senators warn against changing the programs that jack up prices for American sugar.
PhRMA-funded groups the National Hispanic Council on Aging and the National Minority Quality Forum say most voters of color do not support the Democrats' drug pricing reform proposal.
Rep. Cathy McMorris Rodgers (R-Wash.), the ranking member of the Energy and Commerce Committee, has received more business PAC donations this election cycle than any other House candidate.